SBIR/STTR Research Award

Antigen Detection Assay for the Diagnosis of Visceral Leismaniasis

Award identifier 8254a628eb24f565099e86ff0c2641116d9c1a40030ac876576cc179e58fce0cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$481,050

Program and phase

SBIR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DETECTOGEN INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
NBN9JYZKJ4K7
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Antigen detection assay in contrast to conventional serological test, detects disease status and not the host antibody response to the disease etiological agent. It can therefore be used for both diagnosis and disease treatment follow-up purposes. Antigen detection assay has been successfully used for the diagnosis of different infectious diseases including sore throat caused by Streptococcus pyogenes, hepatitis, pneumonia caused by Streptococcus pneumoniae or Legionella pneumophilla, and amoebiasis. Although antigen detection assay has the potential to quickly diagnose active visceral leishmaniasis (VL), paradoxically this test has not yet been fully developed for this serious disease. Using the ultra-sensitive mass spectrometry technology we have recently identified proteins from the etiological agent of VL (Leishmania infantum) in the patients' urine. These findings constitute the foundation of the present project, which aims to use these unique proteins as well as other to be identified to develop a highly sensitive and specific antigen detection assay for the accurate diagnosis of active VL. PUBLIC HEALTH RELEVANCE: This SBIR project aims to develop an antigen detection assay for the diagnosis of visceral leishmaniasis (VL). The general foundation of the proposal is based on the proponent's group finding of Leishmania infantum proteins in the urine of patients with visceral leishmaniasis (VL). Because L. infantum is the etiological agent of VL these findings strongly support the development of an antigen detection assay for the diagnosis this serious disease.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

4 SBIR/STTR records share this UEI (2009–2017). Reported award amounts total $3,831,634. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.